Article
FDA advisers narrowly back accelerated approval of Sarepta gene therapy
Rating:
0.0
Views:
55
Likes:
1
Library:
1
FDA advisers vote 8-6 Friday to recommend the agency grant accelerated approval to Sarepta Therapeutics Inc.'s gene therapy for Duchenne muscular dystrophy.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value